@holoclara.bsky.social
Learn more in this Fierce Biotech article by @megadarren.bsky.social highlighting the start of our clinical trials, lead indication EoE, and plan to expand to other critical indications. www.fiercebiotech.com/research/hol...
Holoclara wriggles roundworm-derived molecule into phase 1, targeting eosinophilic esophagitis
Worm-inspired biotech Holoclara has had a busy year. | Worm-inspired biotech Holoclara has had a busy year. After announcing a $16 million series A round in June, the Pasadena company has now dosed th...
www.fiercebiotech.com
December 18, 2024 at 7:09 PM
Learn more in this Fierce Biotech article by @megadarren.bsky.social highlighting the start of our clinical trials, lead indication EoE, and plan to expand to other critical indications. www.fiercebiotech.com/research/hol...
🩺 Eosinophilic esophagitis is a chronic inflammatory disorder that was historically considered to be an orphan disease. Its prevalence has rapidly grown to 1 in 700 people in the US today, making it the 2nd most common esophageal disease.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...
Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in-Class Worm-Derived Therapy
Holoclara selects eosinophilic esophagitis as its lead indication for HC002, a first-in-class worm-derived therapy
www.businesswire.com
December 18, 2024 at 7:09 PM
🩺 Eosinophilic esophagitis is a chronic inflammatory disorder that was historically considered to be an orphan disease. Its prevalence has rapidly grown to 1 in 700 people in the US today, making it the 2nd most common esophageal disease.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...
💊 Our Phase 1 study will test the safety & tolerability of HC002: an investigational, orally bioavailable small molecule medicine harnessing the therapeutic potential of worms to address historically untreatable diseases.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...
Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults
Holoclara initiates Phase 1 clinical trial evaluating worm-derived therapeutic HC002 in healthy adults
www.businesswire.com
December 18, 2024 at 7:09 PM
💊 Our Phase 1 study will test the safety & tolerability of HC002: an investigational, orally bioavailable small molecule medicine harnessing the therapeutic potential of worms to address historically untreatable diseases.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...
💊 Our Phase 1 study will test the safety & tolerability of HC002: an investigational, orally bioavailable small molecule medicine harnessing the therapeutic potential of worms to address historically untreatable diseases.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...
Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults
Holoclara initiates Phase 1 clinical trial evaluating worm-derived therapeutic HC002 in healthy adults
www.businesswire.com
December 18, 2024 at 6:57 PM
💊 Our Phase 1 study will test the safety & tolerability of HC002: an investigational, orally bioavailable small molecule medicine harnessing the therapeutic potential of worms to address historically untreatable diseases.
Press release: www.businesswire.com/news/home/20...
Press release: www.businesswire.com/news/home/20...